Shots:
- Bio-Thera Solutions & Jamjoom Pharmaceuticals have entered into a strategic agreement to commercialize BAT2306, a biosimilar version of Novartis’ Cosentyx (secukinumab) in the Middle East & Africa (MENA)
- As per the deal, Jamjoom will obtain exclusive MENA rights of BAT2306 to handle regulatory submissions, market access & commercialization, while Bio-Thera will be responsible for development & global manufacturing from its Guangzhou, China facility
- Secukinumab is a fully human IgG1/κ monoclonal antibody targeting IL-17A, which blocks this proinflammatory cytokine to inhibit pathways driving chronic immune-mediated conditions like plaque PsO
Ref: Bio-Thera | Image: Bio-Thera and Jamjoom Pharmaceuticals | Press Release
Related News:- Bio-Thera Secures the EC’s Approval for Usymro (Biosimilar, Stelara)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
